RESUMO
Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10-15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT (AU)
No disponible
Assuntos
Humanos , Masculino , Feminino , /normas , Doença de Hodgkin/patologia , Terapêutica/métodos , Linfócitos/citologia , Transplante de Células/métodos , Espanha/etnologia , Doenças Linfáticas/complicações , Doenças Linfáticas/patologia , Linfonodos/metabolismo , Biópsia por Agulha Fina/métodos , Doença de Hodgkin/complicações , Doença de Hodgkin/diagnóstico , Terapêutica/instrumentação , Linfócitos/fisiologia , Transplante de Células/normas , Transplante de Células , Doenças Linfáticas/genética , Linfonodos/anormalidades , Biópsia por Agulha Fina/instrumentaçãoRESUMO
Follicular non-Hodgkin's lymphoma (FL) is a nodal B lymphoid malignancy that originates from the germinal center of a lymph node. FL is the second most frequent lymphoma subtype. The course of the disease is usually characterised by a typically indolent clinical course, with a median survival rate of 8-10 years, although most patients relapse after treatment. Diagnosis should always be based on a surgical specimen like an excisional node lymph biopsy. The first-line treatment of FL will depend of extension disease, tumour burden, patient symptoms, performance status and also patient decision. The addition of rituximab to conventional chemotherapy has improved ORR, PFS and OS. As first line in patients that need treatment, a combination of chemotherapy with rituximab induction followed by 2 years of rituximab maintenance is the best option. High-dose chemotherapy with autologous stem-cell transplantation in first line has not shown improvement and is not recommended as first-line therapy. Before any treatment decision in relapsed patients, a repeat biopsy is mandatory to rule out a transformation into large cell aggressive lymphoma. Standard treatment is controversial, depends on the efficacy of prior treatment, duration of the time-to-relapse, patients age and histological findings at relapse (AU)
No disponible
Assuntos
Humanos , Masculino , Feminino , /normas , Linfoma Folicular/metabolismo , Linfoma Folicular/patologia , Linfoma não Hodgkin/diagnóstico , Linfoma não Hodgkin/metabolismo , Linfonodos/anormalidades , Linfonodos/metabolismo , Tomografia Computadorizada por Raios X/métodos , Preparações Farmacêuticas/administração & dosagem , Preparações Farmacêuticas/metabolismo , Linfoma Folicular/complicações , Linfoma Folicular/diagnóstico , Linfoma não Hodgkin/classificação , Linfoma não Hodgkin/patologia , Linfonodos/lesões , Tomografia Computadorizada por Raios X/instrumentação , Preparações Farmacêuticas/classificação , Preparações FarmacêuticasRESUMO
Follicular non-Hodgkin's lymphoma (FL) is a nodal B lymphoid malignancy that originates from the germinal center of a lymph node. FL is the second most frequent lymphoma subtype. The course of the disease is usually characterised by a typically indolent clinical course, with a median survival rate of 8-10 years, although most patients relapse after treatment. Diagnosis should always be based on a surgical specimen like an excisional node lymph biopsy. The first-line treatment of FL will depend of extension disease, tumour burden, patient symptoms, performance status and also patient decision. The addition of rituximab to conventional chemotherapy has improved ORR, PFS and OS. As first line in patients that need treatment, a combination of chemotherapy with rituximab induction followed by 2 years of rituximab maintenance is the best option. High-dose chemotherapy with autologous stem-cell transplantation in first line has not shown improvement and is not recommended as first-line therapy. Before any treatment decision in relapsed patients, a repeat biopsy is mandatory to rule out a transformation into large cell aggressive lymphoma. Standard treatment is controversial, depends on the efficacy of prior treatment, duration of the time-to-relapse, patient's age and histological findings at relapse.
Assuntos
Linfoma não Hodgkin/diagnóstico , Linfoma não Hodgkin/terapia , Guias de Prática Clínica como Assunto/normas , Ensaios Clínicos como Assunto , Terapia Combinada , Gerenciamento Clínico , Detecção Precoce de Câncer , Humanos , Oncologia , Estadiamento de Neoplasias , Prognóstico , Sociedades MédicasRESUMO
Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10-15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.
Assuntos
Doença de Hodgkin/diagnóstico , Doença de Hodgkin/terapia , Guias de Prática Clínica como Assunto/normas , Ensaios Clínicos como Assunto , Terapia Combinada , Gerenciamento Clínico , Detecção Precoce de Câncer , Humanos , Oncologia , Estadiamento de Neoplasias , Prognóstico , Sociedades MédicasRESUMO
Hodgkin's lymphoma is a malignant disease with an incidence of 2.2 cases/100,000. The main goals of staging are to measure the extent of disease and associated prognostic factors. Distinct recommendations were produced for initial work-up, first-line therapy of early and advanced stage disease and treatment of relapsed or resistant patients (AU)
Assuntos
Humanos , Masculino , Feminino , Doença de Hodgkin/epidemiologia , Doença de Hodgkin/terapia , Oncologia/métodos , Oncologia/organização & administração , Oncologia/tendências , Guias de Prática Clínica como Assunto , Algoritmos , Sociedades Médicas/organização & administração , Sociedades Médicas/normas , Sociedades Médicas , Espanha/epidemiologiaRESUMO
El carcinoide de células globoides, también denominadoadenocarcinoide, carcinoma mucinoso, ycarcinoma de células de la cripta, es una rara neoplasiacon características específicas clínicas y patológicas.Revisamos el manejo del carcinoide decélulas globoides del apéndice aprovechando la presentaciónde un caso clínico ilustrativo
Goblet cell carcinoid, also variably known asadenocarcinoid, mucinous carcinoid, and crypt cellcarcinoma, is a rare neoplasm with distincthistological and clinical features. We review themanagement of goblet cell carcinoid of theappendix using an illustrative case report